Clinical Trials Logo

Acute Kidney Injury (AKI) clinical trials

View clinical trials related to Acute Kidney Injury (AKI).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05068167 Completed - Clinical trials for Acute Kidney Injury (AKI)

Acute Kidney Injury as a Risk Factor for Myocardial Injury After Non Cardiac Surgery

Start date: March 1, 2019
Phase:
Study type: Observational

The incidence of acute kidney injury (AKI) postoperatively has been identified to be 21.6% in adults and 18.3% in hospitalized individuals. Surgery-related AKI is a severe complication that is related not only to short-term complications as increases in mortality rate and development of cardiac complications but also with complications on long term, such as development of chronic kidney disease. A better understanding of the mechanism of this hypthesis will lead to better management of this complication.

NCT ID: NCT04829916 Completed - Clinical trials for Acute Kidney Injury (AKI)

A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

Start date: March 16, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the clinical study is to assess safety, tolerability and pharmacokinetics of RMC-035 for the prevention and treatment of acute kidney injury (AKI) in patients undergoing cardiac surgery.

NCT ID: NCT04165369 Completed - Clinical trials for Acute Kidney Injury (AKI)

Observational Study to Evaluate the Epidemiology of Surgical-induced Acute Kidney Injury

Epis-AKI
Start date: June 9, 2020
Phase:
Study type: Observational

The evaluation of an accurate occurrence rate for AKI is of great importance for health policy, quality initiatives as well as for designing clinical trials. The primary objective is to prospectively evaluate the incidence of AKI within 72 h after extended surgical procedures that require admission to an observation unit.

NCT ID: NCT03941483 Completed - Clinical trials for Acute Kidney Injury (AKI)

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

Start date: November 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy of postsurgery treatment with ASP1128 in subjects at risk for AKI following CABG and/or valve surgery. This study also investigated the safety and tolerability of postsurgery treatment with ASP1128, and pharmacokinetic characteristics of ASP1128 in subjects at risk for AKI following CABG and/or valve surgery.

NCT ID: NCT02733328 Completed - Clinical trials for Chronic Kidney Disease (CKD)

Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study

NGAL
Start date: May 2016
Phase:
Study type: Observational

The study aims to recruit 156 (54 Acute Kidney Injury (AKI);102 non-AKI) patients undergoing Cardio pulmonary bypass (CPB) surgery, including those with Chronic Kidney Disease (CKD) and multiple co-morbidities. Urine and blood samples collected pre-operatively and then 0, 3, 6 and 18 hours post-CPB will be stored at -80oC until batch analysed for NGAL using the Abbott and BioPorto assays. AKI - defined as a ≥50% rise in serum creatinine (SCr) over baseline, or the requirement for renal replacement therapy (RRT). SCr will be measured pre-operatively (baseline), then 12 hourly for the first 48 hrs post-CPB and thereafter 24 hourly for 5 days. Clinical data collected will include patient demographics, co-morbidities, drug history, pre-operative renal function, surgery details (type, length, CPB time etc.), length of Intensive treatment unit and hospital stay and post-operative complications. Data will then be analysed comparing the two NGAL tests to find out which is superior, whether it is better to use blood or urine and to define optimal NGAL cut-offs and sample timing for predicting AKI. Both the Abbott and BioPorto assays will subject to a laboratory method evaluation prior to the analysis of any patient specimens in order to verify that their performance is acceptable and meets the manufacturer's claims. This will involve measuring the standard parameters used to assess laboratory assay performance e.g. imprecision (reproducibility), linearity, recovery and method comparison etc.